NBP
NovaBridge·NASDAQ
--
--(--)
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NBP
Novabridge Biosciences
A global biotechnology platform company that focuses on the fields of tumors and autoimmune diseases, committed to promoting China's innovative drugs to go global
Biotechnology Ⅲ
06/30/2016
01/17/2020
NASDAQ Stock Exchange
30
12-31
Depository Receipts (Ordinary Shares)
2440 Research Boulevard
Suite 400
Rockville
MD 20850
United States
Develops precision immuno-oncology agents.
Newbridge Bio was incorporated in the Cayman Islands on June 30, 2016. The company is a global biotechnology platform focused on the development of innovative immuno-oncology therapies. Its R&D pipeline includes three clinical-stage projects, of which givastomig, a CLDN 18.2 bispecific antibody for the treatment of gastric cancer, is the company's core product. Through its subsidiary Visara, the company is also developing VIS-101 for retinal diseases.
Company Financials
EPS
NBP has released its 2025 Q4 earnings. EPS was reported at -0.22, versus the expected -0.18, missing expectations. The chart below visualizes how NBP has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
